NanoRepro AG is an innovative leader in the development, manufacturing and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use, in the domestic and international markets. Since October 2008, NanoRepro has been publicly listed with its headquarters located in Marburg, Germany. Our goal is to provide accuracy in self-diagnostics for rapid disease detection.
Self-diagnostics is a fast growing market shaped by the ever-increasing health conscious of the population and healthcare spending. Our rapid diagnostic tests offer significant advantages over all available competitive products due to our flexibility in product design, in-depth market understanding and best practices of just-in-time manufacturing. Our most important success factor is continuous optimization of manufacturing costs. We create values for our customers, shareholders and employees.
The company has currently 20 rapid diagnostic tests within the portfolio addressing various healthcare needs (family planning, preventive healthcare, allergies, and infectious diseases).
Market capitalization (26-May-2017)
Closing share price (26-May-2017)